Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.35 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.35 |
| ▸ | SMO | Q99835 | 2/20 | 0.35 |
| ▸ | KDM1A | O60341 | 2/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | XDH | P47989 | 1/20 | 0.33 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12987181 | 1.00 | GRM5 (0.36) | GRM5PIK3CAPIK3R1SMOKDM1A | |
| SCHEMBL12987565 | 1.00 | GRM5 (0.36) | GRM5PIK3CAPIK3R1SMOKDM1A | |
| SCHEMBL13192630 | 1.00 | GRM5 (0.36) | GRM5PIK3CAPIK3R1SMOKDM1A | |
| SCHEMBL15420624 | 0.94 | SMO (0.40) | GRM5SMOKDM1AXDHADAM17 | |
| SCHEMBL15441169 | 0.94 | SMO (0.40) | GRM5SMOKDM1AXDHADAM17 | |
| SCHEMBL15420514 | 0.93 | GRM5 (0.36) | GRM5PIK3CAPIK3R1SMOKDM1A | |
| SCHEMBL12987780 | 0.92 | GRM5 (0.36) | GRM5PIK3CAPIK3R1KDM1AGRM4 | |
| SCHEMBL15420672 | 0.92 | GRM5 (0.36) | GRM5PIK3CAPIK3R1KDM1AGRM4 | |
| SCHEMBL12987659 | 0.92 | GRM5 (0.36) | GRM5PIK3CAPIK3R1KDM1AGRM4 | |
| SCHEMBL12988095 | 0.91 | SMO (0.40) | GRM5SMOFFAR1ADAM17HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2694472-B1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2020-03-11 | — | — | EP | disclosed |
| US-9527807-B2 | Sulfonamide derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-12-27 | — | — | US | disclosed |
| US-20140024650-A1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024650-A1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | GRIN2A, GRIN2B, SLC1A2 | GRM5 9/4885PIK3CA 2240/4885PIK3R1 1959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.